Jeet Mukherjee
Stock Analyst at BTIG
(3.41)
# 830
Out of 5,240 analysts
48
Total ratings
48.94%
Success rate
5.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Buy | $16 → $18 | $9.87 | +82.37% | 4 | May 13, 2026 | |
| VSTM Verastem | Maintains: Buy | $19 → $18 | $4.72 | +281.36% | 5 | May 8, 2026 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $31.70 | +294.32% | 1 | May 1, 2026 | |
| AAPG Ascentage Pharma Group International | Reiterates: Buy | $48 | $21.38 | +124.51% | 3 | Apr 13, 2026 | |
| AARD Aardvark Therapeutics | Reiterates: Buy | $9 | $6.59 | +36.57% | 4 | Mar 24, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $3.82 | +266.49% | 4 | Mar 17, 2026 | |
| IPHA Innate Pharma | Assumes: Buy | $8 | $1.32 | +506.06% | 1 | Mar 12, 2026 | |
| IBRX ImmunityBio | Assumes: Buy | $13 | $8.15 | +59.51% | 1 | Mar 12, 2026 | |
| AVBP ArriVent BioPharma | Assumes: Buy | $42 | $28.93 | +45.20% | 1 | Mar 12, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $138 → $134 | $85.59 | +56.56% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $192 → $215 | $120.57 | +78.32% | 5 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $104 | $61.44 | +69.27% | 6 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $16.18 | +85.41% | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $20.99 | +33.40% | 1 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.17 | +163.79% | 1 | Dec 18, 2025 |
Arvinas
May 13, 2026
Maintains: Buy
Price Target: $16 → $18
Current: $9.87
Upside: +82.37%
Verastem
May 8, 2026
Maintains: Buy
Price Target: $19 → $18
Current: $4.72
Upside: +281.36%
Viking Therapeutics
May 1, 2026
Reiterates: Buy
Price Target: $125
Current: $31.70
Upside: +294.32%
Ascentage Pharma Group International
Apr 13, 2026
Reiterates: Buy
Price Target: $48
Current: $21.38
Upside: +124.51%
Aardvark Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $9
Current: $6.59
Upside: +36.57%
Perspective Therapeutics
Mar 17, 2026
Reiterates: Buy
Price Target: $14
Current: $3.82
Upside: +266.49%
Innate Pharma
Mar 12, 2026
Assumes: Buy
Price Target: $8
Current: $1.32
Upside: +506.06%
ImmunityBio
Mar 12, 2026
Assumes: Buy
Price Target: $13
Current: $8.15
Upside: +59.51%
ArriVent BioPharma
Mar 12, 2026
Assumes: Buy
Price Target: $42
Current: $28.93
Upside: +45.20%
Kymera Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $138 → $134
Current: $85.59
Upside: +56.56%
Feb 25, 2026
Maintains: Buy
Price Target: $192 → $215
Current: $120.57
Upside: +78.32%
Feb 23, 2026
Reiterates: Buy
Price Target: $104
Current: $61.44
Upside: +69.27%
Jan 29, 2026
Reiterates: Buy
Price Target: $30
Current: $16.18
Upside: +85.41%
Jan 8, 2026
Initiates: Buy
Price Target: $28
Current: $20.99
Upside: +33.40%
Dec 18, 2025
Initiates: Buy
Price Target: $11
Current: $4.17
Upside: +163.79%